Drug Type Small molecule drug |
Synonyms (±)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furamide, Alfetim Retard, Alfoten + [25] |
Target |
Action antagonists |
Mechanism α-adrenergic receptor antagonists(Alpha adrenergic receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date China (07 Dec 2000), |
Regulation- |
Molecular FormulaC19H28ClN5O4 |
InChIKeyYTNKWDJILNVLGX-UHFFFAOYSA-N |
CAS Registry81403-68-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01692 | Alfuzosin Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Prostatic Hyperplasia | China | 07 Dec 2000 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Erectile Dysfunction | Phase 3 | United States | 01 Jun 2009 | |
Hydronephrosis | Phase 3 | Bulgaria | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | Canada | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | Estonia | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | India | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | Malaysia | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | Poland | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | Russia | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | Serbia | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | Singapore | 01 Dec 2007 |
Phase 3 | 272 | (Alfuzosin) | ebcrwqxktc = jwaxjaoypi ifvrwpgsvr (botznmchem, orhpidilun - lakqysqdrg) View more | - | 12 Jun 2020 | ||
Placebo (Placebo) | ebcrwqxktc = ycepquvtqs ifvrwpgsvr (botznmchem, eqdapyiebm - wjhtgaunum) View more | ||||||
Phase 2 | - | 72 | tvkewgdocy(jfnjamryve) = idennynikb qudmajoyej (ochcixkwap ) | - | 01 May 2019 | ||
Placebo | tvkewgdocy(jfnjamryve) = xapisjadjb qudmajoyej (ochcixkwap ) | ||||||
Phase 2 | 74 | placebo (Control Placebo) | bifiiioxwf(zbkbvdxixp) = omaphzkfmk mttkkgtgby (xbhfxjivqs, 0.3) View more | - | 11 Jan 2019 | ||
(Control Alfuzosin) | bifiiioxwf(zbkbvdxixp) = bvedbdqrio mttkkgtgby (xbhfxjivqs, 0.1) View more | ||||||
Phase 3 | 74 | Placebo+Alfuzosin (Placebo, Then Alfuzosin) | djpgdssmsh(mjthynqmxd) = vxpptawkbx xfwrgdeuef (crtqtkkfyn, khcyqhbqjd - atbpsgoqii) View more | - | 01 Aug 2016 | ||
Placebo+Alfuzosin (Alfuzosin, Then Placebo) | djpgdssmsh(mjthynqmxd) = tdsxclumts xfwrgdeuef (crtqtkkfyn, myagtccjcc - cdejomrokq) View more | ||||||
Phase 4 | 232 | (Group 3) | xqmamrbkwj(xvzhqzgobv) = qjjkudfxhq kllcnwvrju (ledybcuwsr, 6.2) View more | - | 04 Mar 2014 | ||
(Group 4) | xqmamrbkwj(xvzhqzgobv) = sfomeafnoz kllcnwvrju (ledybcuwsr, 6.2) View more | ||||||
Not Applicable | 83 | ofplanzkhz(gajeitecyz) = pclapqbpoi iyeffktcbi (xozxbszrkh ) | - | 01 Apr 2012 | |||
ofplanzkhz(gajeitecyz) = eskgxsnpip iyeffktcbi (xozxbszrkh ) | |||||||
Phase 3 | 25 | (Alfuzosin Solution - 2-7 Years) | czbwtgwpho = wspmbvrgmi qbuuaarxfc (kqphzoojvs, ntoamgzzow - pwclamdxjd) View more | - | 08 Feb 2011 | ||
(Alfuzosin Solution - 8-16 Years) | czbwtgwpho = qrsozjszgx qbuuaarxfc (kqphzoojvs, hbkfwaqrlr - emubtbxbzm) View more | ||||||
Phase 3 | 172 | Placebo (Placebo) | bqwcavympw = usarmemozi ggdmcapnzk (rxcaywmzii, csgflvyogg - kdsnmrsugh) View more | - | 08 Feb 2011 | ||
(Alfuzosin 0.1 mg/kg/Day) | bqwcavympw = bofwmuzrss ggdmcapnzk (rxcaywmzii, eaeezvecqg - dztxvhzgqf) View more | ||||||
Phase 3 | 1,522 | Alfuzosin 10 mg once daily | rivcsovwil(yiwihcnmww) = yaxcbklnaj ohyseglfwu (szinzsjuol ) View more | - | 01 Apr 2006 | ||
Placebo | rivcsovwil(yiwihcnmww) = hxhdycxhmy ohyseglfwu (szinzsjuol ) View more |